Field Safety Notices: 6 November 2024
A weekly index of the field safety notices manufacturers issued that week.
Source · Drug & device safety alerts
MHRA Drug & Device Safety Alerts
1,501 individual alerts
447 medicines recalls & defect notices
766 weekly / monthly index pages
Oct 2009 – Jul 2026
Drug safety updates, medicines recalls, device safety information and field safety notices published by the Medicines and Healthcare products Regulatory Agency. Source: MHRA alerts and recalls on GOV.UK.
Showing 2,267 publications of 2,267
Class 2 Medicines Recall: Tillomed Laboratories Limited, Labetalol 200mg Tablets, EL(24)A/52
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 30th October 2024
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 21 to 25 October 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Kent Pharma UK, Parasolve (Paracetamol) 500mg effervescent tablets, EL(24)A/51
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
UPDATE: Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Ltd Cyanocobalamin 50 mcg Tablets, EL(24)A/46
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in September 2024
A periodic index page listing other alerts and letters, not a single alert.
GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
An article in MHRA's monthly Drug Safety Update bulletin.
Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme
An article in MHRA's monthly Drug Safety Update bulletin.
Class 2 Medicines Recall: Bristol Laboratories Ltd, Phenobarbital Bristol Labs 15mg Tablets, EL(24)A/50
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 14 to 18 October 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Kent Pharma UK, Paracetamol 500mg Effervescent Tablets, EL(24)A/49
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 18 October 2024
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 7 to 11 October 2024
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 7 October to 14 October 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Sandoz Ltd., Linezolid 600 mg film-coated tablets, EL(24)A/48
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 30 September to 4 October 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Viatris UK Healthcare Ltd, Trandolapril 2mg and 4mg capsules, EL(24)A/47
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Class 4 Medicines Defect Information: Sandoz Ltd., Rosuvastatin 20mg, 40mg Tablets, EL(24)A/45
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 2 Medicines Recall: Pfizer Limited, Oxbryta 500mg Tablets (voxelotor), EL(24)A/44
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices: 23 to 27 September 2024
A weekly index of the field safety notices manufacturers issued that week.
Letters and medicine recalls sent to healthcare professionals in August 2024
A periodic index page listing other alerts and letters, not a single alert.
Class 4 Medicines Defect Information: Sandoz Ltd., Risperidone 1mg, 2mg, 3mg Tablets, EL(24)A/43
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 16 to 20 September 2024
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices: 9 to 13 September 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Orion Pharma (UK) Ltd, Eldepryl 5mg Tablets (selegiline), EL(24)A/42
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Class 3 Medicines Recall: Theramex HQ UK Ltd, Evorel Sequi, EL (24)A/41
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Field Safety Notices: 2 to 6 September 2024
A weekly index of the field safety notices manufacturers issued that week.
Valproate use in men: as a precaution, men and their partners should use effective contraception
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notices: 26 to 30 August 2024
A weekly index of the field safety notices manufacturers issued that week.
CPT Hip System Femoral Stem 12/14 Neck Taper: Increased Risk of Postoperative Periprosthetic Femoral Fracture, DSI/2024/007
Field Safety Notices: 19 to 23 August 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Chemidex Pharma Ltd, Ponstan 250mg Capsules & 500mg Tablets (mefenamic acid), EL(24)A/40
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Yellow Card Biobank: call to contribute to study of genetic links to side effects
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and medicine recalls sent to healthcare professionals in July 2024
A periodic index page listing other alerts and letters, not a single alert.
Field Safety Notices: 12 to 16 August 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Ltd, Fingolimod 0.5 mg Hard Capsules, EL(24)A/39
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Field Safety Notices: 5 to 9 August 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Strides Pharma UK Limited, Loperamide Hydrochloride Capsules 2mg, EL(24)A/38
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Class 4 Medicines Defect Information: Dawa Limited, Trazodone Hydrochloride 50mg, 100mg Capsules & 50mg/5ml Oral Solution, EL (24)A/37
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 4 Medicines Notification, Star Pharmaceuticals Limited, Diflucan Oral Suspension 40mg/ml, EL(24)A36
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 3 Medicines Recall: Accord-UK Ltd, Trandolapril 0.5mg, 2mg, 4mg Capsules, EL(24)A/35
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Class 4 Medicines Defect Information: Sandoz Limited, Omeprazole products, EL(24)A/34
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices: 29 July to 2 August 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Ltd, Atomoxetine 10mg, 18mg, 25mg, 10mg, 40mg, 60mg, 80mg & 100mg Hard Capsules, EL(24)A/33
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Field Safety Notices: 22 to 26 July 2024
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Aspen Pharma Trading Limited, Co-trimoxazole 80mg/400mg per 5ml adult suspension, EL (24)A/32
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 4 Medicines Defect Information: Fresenius Kabi Limited, Hartmann's Solution for Injection BP as Steriflex No. 11 or freeflex, EL(24)A/31
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Letters and medicine recalls sent to healthcare professionals in June 2024
A periodic index page listing other alerts and letters, not a single alert.
About this source
Individual alerts by type
Read the chart values
| Alert type | Individual alerts |
|---|---|
| Drug Safety Update | 713 |
| Class 1 Medicines Recall | 6 |
| Class 2 Medicines Recall | 159 |
| Class 3 Medicines Recall | 68 |
| Class 4 Medicines Defect Information | 179 |
| Company-Led Medicines Recall | 35 |
| Device Safety Information | 21 |
| Medical Device Alert | 40 |
| National Patient Safety Alert | 11 |
| MHRA Safety Roundup | 16 |
| Unclassified | 253 |
The MHRA regulates medicines and medical devices in the UK and publishes safety communications on GOV.UK in two streams: the monthly Drug Safety Update bulletin, and Alerts and recalls for drugs and medical devices. This page holds 2,267 of those publications, issued between October 2009 and July 2026.
MHRA classes a medicines recall by the hazard the defect presents: Class 1 life-threatening or serious, Class 2 could cause illness or mistreatment, Class 3 unlikely to cause harm, and Class 4 a caution in use rather than a recall, with the product staying available. A device notice is published as Device Safety Information, or, until 2021, as a Medical Device Alert.
What is not here. We hold each publication's title, type, date and link, not its text: read the alert on GOV.UK for the affected products and the actions MHRA asks for. An alert names a medicine or device and a clinical audience, not an organisation, so no alert on this page is linked to an NHS trust or other responsible body. The weekly “Field Safety Notices” pages are MHRA's own index of the notices manufacturers issued that week, not single alerts, and are counted separately above.